Unlock all Features See Plans and Pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Merck
Moodys
McKesson
Mallinckrodt
Colorcon

Last Updated: December 3, 2022

CLINICAL TRIALS PROFILE FOR PLETAL


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


All Clinical Trials for Pletal

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00048763 ↗ Safety and Efficacy of Pletal(Cilostazol) for the Treatment of Juvenile Primary and Secondary Raynaud's Phenomenon Completed Otsuka America Pharmaceutical Phase 4 2001-10-01 Juvenile primary Raynaud's (ray-knows) Phenomenon is a disorder of the blood vessels in the fingers and sometimes can affect the toes, nose, or ears. When children with primary Raynaud's Phenomenon are exposed to chilly or cold conditions from weather, cold temperatures, or even holding cold items from the refrigerator, their fingers may become cold, numb, hurt, and/or turn purple or white. Children with primary Raynaud's Phenomenon have no underlying systemic disease. The cause for their symptoms is unknown. The investigational drug, Pletal(cilostazol), which has been approved for other conditions, inhibits the ability of one type of blood cell, platelets, to form blood clots, and also widens narrowed blood vessels. It has been used in a variety of other conditions in which blood flow is decreased. This study will test the safety and effectiveness Pletal(cilostazol) to lessen the severity of the symptoms and decrease the number of primary Raynaud's episodes in juvenile patients.
NCT00048776 ↗ Safety and Efficacy of Pletal (Cilostazol) for the Treatment of Juvenile Primary and Secondary Raynaud's Phenomenon Completed Otsuka America Pharmaceutical Phase 4 2001-10-01 Juvenile secondary Raynaud's (ray-knows) Phenomenon is a disorder of the blood vessels in the fingers and sometimes can affect the toes, nose, or ears. Children with secondary Raynaud's Phenomenon have an underlying condition such as systemic lupus, scleroderma, or mixed connective tissue disease. When children with secondary Raynaud's are exposed to chilly or cold conditions from weather, cold temperatures, or even holding cold items from the refrigerator, their fingers may become cold, numb, hurt, and/or turn purple or white. The investigational drug, Pletal(cilostazol), which has been approved for other conditions, inhibits the ability of one type of blood cell, platelets, to form blood clots, and also widens narrowed blood vessels. It has been used in a variety of other conditions in which blood flow is decreased. This study will test the safety and effectiveness Pletal(cilostazol) to lessen the severity of the symptoms and decrease the number of secondary Raynaud's episodes in juvenile patients.
NCT00602173 ↗ Bioequivalency Study of 100 mg Cilostazol Tablets Under Fasting Conditions Completed Roxane Laboratories N/A 2003-05-01 The objective of this study was the bioequivalence of a Roxane Laboratories' Cilostazol Tablets, 100 mg, to PLETAL® Tablets, 100 mg (OTSUKA Pharmaceuticals) under fasting conditions using a single-dose, randomized, 3-treatment, 3-period, crossover design.
NCT00602407 ↗ Bioequivalency Study of 50 mg Cilostazol Tablets Under Fasting Conditions Completed Roxane Laboratories N/A 2004-02-01 The objective of this study was the bioequivalence of a Roxane Laboratories' Cilostazol Tablets, 50 mg, to PLETAL® Tablets, 50 mg (OTSUKA Pharmaceuticals) under fasting conditions using a single-dose, randomized, 2-treatment, 2-period, crossover design.
NCT00648388 ↗ Fasting Study of Cilostazol Tablets 100 mg and Pletal® Tablets 100 mg Completed Mylan Pharmaceuticals Phase 1 2004-03-01 The objective of this study was to investigate the bioequivalence of Mylan's cilostazol 100 mg tablets and Otsuka's Pletal® 100 mg tablets following a single, oral 100 mg(1 x 100 mg) dose administered under fasting conditions.
NCT00684762 ↗ Fasted Bioavailability Study of Cilostazol Tablets, 100 mg Completed Mutual Pharmaceutical Company, Inc. Phase 1 2004-03-01 The purpose of this study is to evaluate and compare the relative bioavailability of a test formulation of cilostazol tablets to an equivalent dose of Pletal® (cilostazol) tablets after a single oral dose administered under fasting conditions.
NCT00685802 ↗ Fasted Bioavailability Study of Cilostazol Tablets, 50mg Completed Mutual Pharmaceutical Company, Inc. Phase 1 2004-06-01 The purpose of this study is to evaluate and compare the relative bioavailability of a test formulation of cilostazol tablets to an equivalent dose of Pletal® (cilostazol) tablets after a single oral dose administered under fasting conditions.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Pletal

Condition Name

Condition Name for Pletal
Intervention Trials
Intermittent Claudication 4
Migraine 3
Peripheral Arterial Disease 2
Raynaud's Disease 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Pletal
Intervention Trials
Intermittent Claudication 5
Migraine Disorders 4
Headache 4
Raynaud Disease 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Pletal

Trials by Country

Trials by Country for Pletal
Location Trials
United States 50
Denmark 5
Germany 1
United Kingdom 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Pletal
Location Trials
California 4
Massachusetts 3
Texas 3
Ohio 3
New York 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Pletal

Clinical Trial Phase

Clinical Trial Phase for Pletal
Clinical Trial Phase Trials
Phase 4 5
Phase 2 2
Phase 1 6
[disabled in preview] 7
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Pletal
Clinical Trial Phase Trials
Completed 17
Unknown status 2
Terminated 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Pletal

Sponsor Name

Sponsor Name for Pletal
Sponsor Trials
Danish Headache Center 4
Otsuka America Pharmaceutical 2
Roxane Laboratories 2
[disabled in preview] 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Pletal
Sponsor Trials
Other 13
Industry 11
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Merck
McKesson
Medtronic
Mallinckrodt
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.